Search fresh public links, source activity, and post angles for Alzheimer's Drug Trial.
Fresh curated links around Alzheimer's Drug Trial are collected here so marketers can spot useful updates and turn timely ideas into posts faster.
Recent items include:
Recent curated links from global sources. Generate one free draft from any story, then use SocialBu to schedule and refine your content calendar.
This month, a group of researchers published an annual report on the clinical trials that are testing drugs for Alzheimer’s disease. Overall, they reported an increase in the numbe...
An experimental drug is showing promise by targeting Alzheimer’s disease at the level of gene regulation. Researchers at the University of Barcelona have developed an experimental...
GSK and Alector have stopped a phase 2 trial of their Alzheimer’s disease drug candidate after an interim analysis found the study was unlikely to hit its primary endpoint.
A critical research lette exposes severe flaws in "quantile aggregation", a statistical technique recently used by pharmaceutical researchers to evaluate the drug donanemab.
One of the company’s more closely watched research assets, BIIB080 is now heading to late-stage testing based on “the strength of the biomarker and efficacy data” seen in a Phase 2...
THURSDAY, April 16, 2026 — New anti-amyloid drugs approved to treat Alzheimer’s disease have no clinically meaningful positive effects for patients, a major evidence review has co...
By Zachary Stieber A class of Alzheimer’s drugs that have only been available for several years did not appear to have any “clinically meaningful effects,” according to a new revie...
The PREVAiLS study, believed to be the only recruiting phase 3 ALS trial, aims to slow disease progression and preserve function in early-stage patients.
The anti-amyloid drug class has yielded some FDA approvals and plenty of failed candidates. Now, researchers are looking at the overall track record of the group and painting an un...
Behavioral neurology expertise and expanded patient access support final phase of recruitment in Alzheimer's agitation study
Behavioral neurology expertise and expanded patient access support final phase of recruitment in Alzheimer's agitation study
Severe dopamine dysfunction in the entorhinal cortex is a primary, hidden mechanism behind Alzheimer's-related memory impairment. Researchers found that dopamine levels in this vit...
The review said a certain class of drugs had little clinical benefit, but many Alzheimer’s experts criticized the analysis, saying it unfairly lumped failed drugs with two recently...
Discover how Cognition Therapeutics is redefining hope for Alzheimer’s and Dementia with Lewy bodies [JG1] with innovative, accessible therapies.
The brain scans look unambiguous. After 18 months of treatment, the amyloid plaques that riddle the brains of early Alzheimer’s patients are visibly reduced, sometimes dramatica...
IGC Pharma reaches 80% enrollment in its Phase 2 CALMA Alzheimer’s trial, advancing toward completion, data readout, and a major clinical catalyst in 2026.
Drugs that are said to slow the progression of Alzheimer's disease "make no meaningful difference to patients" while increasing the risk of swelling and bleeding in the brain, acco...
A phase 2 trial of Biogen and Ionis Pharmaceuticals’ tau-targeting candidate missed its primary endpoint. But while the Alzheimer’s disease trial failed to yield the hoped-for dose...
Drugs designed to clear amyloid beta from the brain—once seen as a promising path to slowing Alzheimer’s—may not actually help patients in any meaningful way, according to a major...
A scientific report has raised questions about how much Leqimbi and Kisunla — the “breakthrough” Alzheimer’s drugs that have hit the market in the last few years — really help slow...
The calling card of Alzheimer’s disease is a buildup of misfolded amyloid protein in the brain, but many medicines struggle to penetrate the barrier protecting the mind from outsid...
These drugs were hailed by proponents as breakthroughs in the fight to treat Alzheimer’s disease, but a new independent review finds they make “no meaningful difference”
In the context of Alzheimer's disease, the data for anti-amyloid immunotherapies, the most recent of which do effectively clear the aggregation of amyloid-β in the brain, is not co...
Researchers say an experimental Alzheimer's drug may calm brain inflammation linked to alcohol withdrawal, potentially reducing relapse and neural damage.
Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.